30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

ContraFect Corp (CFRX)

Track

Stock chart
Ticker: CFRX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Sucoff Cary
1 purchase — total 19,500 USD
Buy 13 Dec 2019
Value US$2,328,152.36 | Price 452.11 | Shares 93,540
Buy 13 Dec 2019
Value US$468,043.06 | Price 49.47 | Shares 21,015
Buy 13 Dec 2019
Value US$1,850.00 | Price 0.37 | Shares 5,000
Sale 4 Dec 2018
Value US$1,224,000.00 | Price 2.04 | Shares 600,000
Sale 4 Dec 2018
Value US$1,224,000.00 | Price 2.04 | Shares 600,000
Buy 25 Jul 2017
Value US$19,840.00 | Price 1.24 | Shares 16,000
Buy 25 Jul 2017
Value US$11,904.00 | Price 1.24 | Shares 9,600
Buy 25 Jul 2017
Value US$14,880.00 | Price 1.24 | Shares 12,000
Buy 25 Jul 2017
Value US$9,920.00 | Price 1.24 | Shares 8,000
Buy 25 Jul 2017
Value US$49,600.00 | Price 1.24 | Shares 40,000
Buy 25 Jul 2017
Value US$992.00 | Price 1.24 | Shares 800
Buy 25 Jul 2017
Value US$49,600.00 | Price 1.24 | Shares 40,000
Buy 25 Jul 2017
Value US$992.00 | Price 1.24 | Shares 800
Buy 25 Jul 2017
Value US$992.00 | Price 1.24 | Shares 800
Buy 25 Jul 2017
Value US$992.00 | Price 1.24 | Shares 800
Buy 25 Jul 2017
Value US$9,920.00 | Price 1.24 | Shares 8,000
Buy 25 Jul 2017
Value US$2,480.00 | Price 1.24 | Shares 2,000
Buy 27 Jul 2016
Value US$49,600.00 | Price 2.48 | Shares 20,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2019-12-16 2019-12-13 B Purchase Sucoff Cary Non-Executive Director
93,540 -40.0%
452.11
US$2,328,152 		93,540 -40.0% 452.11 US$2,328,152
2019-12-16 2019-12-13 B Purchase Low David N. Non-Executive Director
21,015 +37.5%
49.47
US$468,043 		21,015 +37.5% 49.47 US$468,043
2019-12-16 2019-12-13 B Purchase Messinger Michael

Chief Financial Officer

Officer
47,421 -37.5%
444.74
US$1,090,974 		47,421 -37.5% 444.74 US$1,090,974
2018-12-06 2018-12-04 S Sale Fosun Industrial Co., Ltd Large shareholder
600,000 -7.1%
2.04
US$1,224,000 		600,000 -7.1% 2.04 US$1,224,000
2018-12-06 2018-12-04 S Sale Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Large shareholder
600,000 -7.1%
2.04
US$1,224,000 		600,000 -7.1% 2.04 US$1,224,000
2017-07-27 2017-07-25 B Purchase BLECH ISAAC Non-Executive Director
16,000 +inf%
1.24
US$19,840 		16,000 +inf% 1.24 US$19,840
2017-07-26 2017-07-25 B Purchase Ricciardi Lisa Non-Executive Director
9,600 +inf%
1.24
US$11,904 		9,600 +inf% 1.24 US$11,904
2017-07-26 2017-07-25 B Purchase Sucoff Cary Non-Executive Director
12,000 +inf%
1.24
US$14,880 		12,000 +inf% 1.24 US$14,880
2017-07-26 2017-07-25 B Purchase Cassino Cara M

Chief Medical Officer

Officer
8,000 +inf%
1.24
US$9,920 		8,000 +inf% 1.24 US$9,920
2017-07-26 2017-07-25 B Purchase Low David N. Non-Executive Director
40,000 +130.9%
1.24
US$49,600 		40,000 +130.9% 1.24 US$49,600
2017-07-26 2017-07-25 B Purchase Bogdanos Natalie

General Counsel

Officer
800 +inf%
1.24
US$992 		800 +inf% 1.24 US$992
2017-07-26 2017-07-25 B Purchase BARER SOL J Non-Executive Director
40,000 +5.2%
1.24
US$49,600 		40,000 +5.2% 1.24 US$49,600
2017-07-26 2017-07-25 B Purchase Messinger Michael

SVP Finance

Officer
800 +6.0%
1.24
US$992 		800 +6.0% 1.24 US$992
2017-07-26 2017-07-25 B Purchase GILMAN STEVEN C

CEO

Executive Director
800 +4.0%
1.24
US$992 		800 +4.0% 1.24 US$992
2017-07-26 2017-07-25 B Purchase Pomerantz Roger Non-Executive Director
800 +inf%
1.24
US$992 		800 +inf% 1.24 US$992
2017-07-26 2017-07-25 B Purchase OTTO MICHAEL J. Non-Executive Director
8,000 +inf%
1.24
US$9,920 		8,000 +inf% 1.24 US$9,920
2017-07-26 2017-07-25 B Purchase Muntner Joshua B

SVP Business Development

Officer
2,000 +inf%
1.24
US$2,480 		2,000 +inf% 1.24 US$2,480
2016-07-27 2016-07-27 B Purchase GILMAN STEVEN C

CEO

Executive Director
20,000 +inf%
2.48
US$49,600 		20,000 +inf% 2.48 US$49,600
Explore more

More insider trading research around ContraFect Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America